6.110USD-3.78%Mkt Cap: 1.51B USDP/E: —Last update: 2026-05-22
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treat…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.51B USD
Enterprise Value1.56B USD
Revenue (TTM)427.68M USD
Gross Profit367.78M USD
Net Income (TTM)-61.60M USD
Revenue/Share1.761 USD
Last Price6.110 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees489
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)12.33
PEG—
EV/EBITDA-45.95
EV/Revenue3.66
P/S3.67
P/B10.55
EPS (TTM)-0.24
EPS (Forward)0.52
52W Range
3.49053% of range8.400
52W High8.400 USD
52W Low3.490 USD
Profitability
Gross Margin90.29%
Oper. Margin-34.71%
EBITDA Margin-7.96%
Profit Margin-15.12%
ROE-36.90%
ROA-12.28%
Growth
Revenue Growth27.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-42.48M USD
CapEx (TTM)1.49M USD
FCF Margin0.02%
FCF Yield0.01%
Net Debt-3.95M USD
Net Debt/EBITDA0.12
Balance Sheet
Debt/Equity1.25
Current Ratio3.48
Quick Ratio2.93
Book Value/Sh0.6020 USD
Cash/Share0.9640 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)16.33 USD
Target Range13.00 USD – 19.00 USD
# Analysts9
Ownership
Shares Out.247.03M
Float219.68M
Insiders3.21%
Institutions70.67%
Short Interest
Short Ratio7.2d
Short % Float9.75%
Short % Out.9.54%
Shares Short23.57M
Short (prev mo.)24.46M
Technical
SMA 506.126 (-0.3%)
SMA 2006.125 (-0.2%)
Beta0.61
S&P 52W Chg28.31%
Avg Vol (30d)3.93M
Avg Vol (10d)3.55M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—